secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clovis Oncology, Inc. (—)
CIK:        0001466301
Form:       8-K
Filed at:   2023-05-01T23:59:59+00:00
Accession:  0001193125-23-130464
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Clovis Oncology completes sale of Rubraca assets to pharma& Schweiz under Chapter 11
--------------------------------------------------------------------------------

- On May 1, 2023, Clovis closed the Rubraca asset sale to pharma& Schweiz GmbH, following court approval on April 12.
- Common stockholders are not expected to receive any payment due to senior creditor claims.
- Sale was part of Chapter 11 bankruptcy proceedings initiated in December 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523130464/0001193125-23-130464-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1466301/000119312523130464/d489588d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-130464

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer